• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.

作者信息

Meinert C L, Knatterud G L, Prout T E, Klimt C R

出版信息

Diabetes. 1970;19:Suppl:789-830.

PMID:4926376
Abstract
摘要

相似文献

1
A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.一项关于降糖药物对成年发病型糖尿病患者血管并发症影响的研究。II. 死亡率结果。
Diabetes. 1970;19:Suppl:789-830.
2
The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy.大学组糖尿病项目。一项关于降糖药物对成年发病型糖尿病患者血管并发症影响的研究。五、苯乙双胍治疗的评估。
Diabetes. 1975;24 Suppl 1:65-184.
3
Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report.
Diabetes. 1982 Nov;31 Suppl 5:1-81.
4
Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results.
JAMA. 1971 Nov;218(9):1400-10.
5
Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. IV. A preliminary report on phenoformin results.
JAMA. 1971 Aug 9;217(6):777-84.
6
Remarks concerning some recent reports on therapy of diabetes.关于近期一些糖尿病治疗报告的评论
Isr J Med Sci. 1972 Jun;8(6):883-7.
7
The UGDP study.
JAMA. 1971 Dec 13;218(11):1704-5.
8
[Sex differences in cardiovascular mortality of diabetics].
Dtsch Med Wochenschr. 1976 May 14;101(20):789-93. doi: 10.1055/s-0028-1104132.
9
[Concepts on the management of diabetic patients].[糖尿病患者管理的相关概念]
Arch Inst Cardiol Mex. 1971 Jan-Feb;41(1):97-105.
10
[25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].口服降糖药治疗糖尿病25年：成功与失败
Journ Annu Diabetol Hotel Dieu. 1984:183-91.

引用本文的文献

1
The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.美国国立糖尿病、消化和肾脏疾病研究所应对1型糖尿病并发症：糖尿病控制与并发症试验/糖尿病干预与并发症流行病学（DCCT/EDIC）研究。
Diabetes Care. 2025 Jul 1;48(7):1089-1100. doi: 10.2337/dc24-2885.
2
Comparison of SGLT1, SGLT2, and Dual Inhibitor biological activity in treating Type 2 Diabetes Mellitus.SGLT1、SGLT2及双重抑制剂在治疗2型糖尿病中的生物学活性比较。
Adv Ther (Weinh). 2023 Dec;6(12). doi: 10.1002/adtp.202300143. Epub 2023 Sep 17.
3
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure.
以血糖为中心的药物在心血管疾病保护和心力衰竭中的应用。
Methodist Debakey Cardiovasc J. 2022 Dec 6;18(5):40-53. doi: 10.14797/mdcvj.1155. eCollection 2022.
4
Sulfonylurea Use in Patients with Type 2 Diabetes and COPD: A Nationwide Population-Based Cohort Study.磺酰脲类药物在 2 型糖尿病合并 COPD 患者中的应用：一项全国性基于人群的队列研究。
Int J Environ Res Public Health. 2022 Nov 15;19(22):15013. doi: 10.3390/ijerph192215013.
5
Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs.对磺酰脲类药物和低血糖风险低的抗糖尿病药物进行头对头试验的系统评价和荟萃分析。
BMC Endocr Disord. 2022 Oct 19;22(1):251. doi: 10.1186/s12902-022-01158-5.
6
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?抗糖尿病药物的血糖外作用：一石二鸟？
Endocrinol Metab (Seoul). 2022 Jun;37(3):415-429. doi: 10.3803/EnM.2022.304. Epub 2022 Jun 29.
7
Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?2 型糖尿病合并糖耐量受损患者的心血管事件和动脉粥样硬化：在这些患者中，有哪些预防心血管事件的医学治疗方法？
J Diabetes Investig. 2022 Jul;13(7):1114-1121. doi: 10.1111/jdi.13799. Epub 2022 Apr 18.
8
Sulfonylureas Use Is Not Associated With Increased Infarct Size in Patients With Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction.磺脲类药物的使用与2型糖尿病合并ST段抬高型心肌梗死患者梗死面积增加无关。
Front Cardiovasc Med. 2021 May 28;8:658059. doi: 10.3389/fcvm.2021.658059. eCollection 2021.
9
Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas.2型糖尿病管理当前实践中的磺脲类药物：它们都一样吗？海湾合作委员会（GCC）国家磺脲类药物咨询委员会的共识
Diabetes Ther. 2021 Aug;12(8):2115-2132. doi: 10.1007/s13300-021-01059-1. Epub 2021 May 13.
10
Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.改变 2 型糖尿病治疗方法：在整个治疗过程中比较胰高血糖素样肽-1 受体激动剂和磺脲类药物。
Diabetes Metab Res Rev. 2021 Oct;37(7):e3434. doi: 10.1002/dmrr.3434. Epub 2021 Feb 7.